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Background: Cancer waiting time targets are routinely monitored in England, but the Cancer Waiting Times monitoring dataset
(CWT) does not include all eligible patients, introducing scope for bias.
Methods: Data from adults diagnosed in England (2009–2013) with colorectal, lung, or ovarian cancer were linked from CWT to
cancer registry, mortality, and Hospital Episode Statistics data. We present demographic characteristics and net survival for
patients who were and were not included in CWT.
Results: A CWT record was found for 82% of colorectal, 76% of lung, and 77% of ovarian cancer patients. Patients not recorded in
CWT were more likely to be in the youngest or oldest age groups, have more comorbidities, have been diagnosed through
emergency presentation, have late or missing stage, and have much poorer survival.
Conclusions: Researchers and policy-makers should be aware of the limitations in the completeness and representativeness of
CWT, and draw conclusions with appropriate caution.
Successive national cancer plans and strategies for England have
included targets to reduce waiting times to diagnosis and treatment
for all cancers (Department of Health, 2000, 2007, 2011;
Independent Cancer Taskforce, 2015). These include a maximum
2-week wait (TWW) between an urgent referral from a general
practitioner (GP) to being seen by a specialist, a maximum 62 days
from the GP’s urgent referral to the start of first treatment, and a
maximum 31 days from the decision to treat a patient to the start
of treatment. A new 28-day target to confirm or exclude a cancer
diagnosis has also been proposed (Independent Cancer Taskforce,
2015).
Waiting time targets are considered to be important indicators
of the quality of cancer care. National cancer waiting time statistics
have been published quarterly by NHS England since 2013 2014
(Cancer Waiting Times Team, 2016) and previously by the
Department of Health. Performance varies widely across the
country: many Clinical Commissioning Groups fall below current
operational standards, and adherence to the 62-day target has been
decreasing since 2014 (Cancer Waiting Times Team, 2016).
The English National Cancer Waiting Times monitoring dataset
(CWT), is the basis for these official statistics. The data are
collected by ‘the provider that is commissioned to deliver the
activity’ (Cancer Waiting Times Team, 2015). CWT only contains
diagnosis and treatment information on cancer patients who were
offered treatment within the NHS, including those who refused
treatment or were assigned to active monitoring (Cancer Waiting
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Times Team, 2015), whichever diagnosis route they came through.
However, not all eligible cancer patients are included and the
extent of incompleteness is unclear. We examine recent CWT data
for three cancers, linked to individual cancer patient data, to
compare the characteristics of patients who were and were not
included in CWT.
MATERIALS AND METHODS
Data sources and study population. All adults (15 99 years)
who were diagnosed in England during 2009 2013 with color-
ectal, non-small cell lung or ovarian cancer were included.
CWT diagnosis and treatment data were linked at individual
level with the national cancer registry data (including vital status at
31 December 2014), the Hospital Episode Statistics data, and the
Routes to Diagnosis dataset (Elliss-Brookes et al, 2012). Demo-
graphic information included age, sex, and deprivation quintile.
Stage at diagnosis and Charlson Comorbidity Index score
(Charlson et al, 1987) were derived using algorithms applied to
these datasets and audit data, where available (Benitez-Majano
et al, 2016; Maringe et al, 2017).
Statistical analysis. We examined the sociodemographic and
clinical characteristics of cancer patients and estimated net survival
at 1 year. We report results by patient age group, deprivation
quintile, and tumour stage. Net survival can be interpreted as
survival from the cancer, accounting for the mortality from other
causes, using life tables of the England general population stratified
by age, sex, calendar year, and region (Spika, 2015).
RESULTS
During 2009 2013, 164 890 colorectal, 171 208 non-small cell
lung, and 24 545 ovarian cancer patients were registered in
England, of whom 82%, 76%, and 77%, respectively, were included
in CWT for first and/or subsequent treatments (Table 1).
The completeness of CWT improved slightly during
2009 2011, more for lung and ovarian cancers than for colorectal
cancer, then plateaued until 2013. The percentage of patients
included varied by patient and tumour factors, with nearly all
differences statistically significant in a w2-test at Po0.001 (Table 1,
Figure 1).
There was a strong J-shaped age pattern in the probability of
inclusion in CWT (Figure 1): the youngest and, especially, the
oldest patients were least likely to be included. Among those older
than 70 years, over a quarter with colorectal cancer and around
40% with lung or ovary cancer had no record in CWT. More
affluent patients were less likely to have a CWT record. Women
with colorectal cancer were slightly less likely to have a CWT
record than men (80.2 vs 82.7%), but there was no evidence of a
difference between the sexes for lung cancer (P¼ 0.211).
A CWT record was missing for more than half of patients whose
route to diagnosis was unknown, and for around a third of those
diagnosed through an emergency presentation.
More than 85% of patients with stage I and II tumours were
recorded in CWT (Figure 1). Among colorectal and lung cancer
patients, those with missing stage were also the most likely to be
missing from CWT, although the proportion was similar to
patients diagnosed at stage IV. Among women with ovarian cancer,
Table 1. Presence of a record in the CWT by selected characteristics of patients
Colorectal cancer Lung cancer Ovarian cancer
Included in CWT
dataset
Yes, n (%) No, n (%) Total
(100%)
Yes, n (%) No, n (%) Total
(100%)
Yes, n (%) No, n (%) Total
(100%)
Total 134 544 (81.6) 30 346 (18.4) 164 890 129 765 (75.8) 41 443 (24.2) 171 208 18900 (77.0) 5645 (23.0) 24 545
Year of diagnosis
2009 25 731 (79.5) 6616 (20.5) 32 347 23 652 (71.7) 9355 (28.3) 33 007 3630 (72.5) 1374 (27.5) 5004
2010 26 698 (81.8) 5934 (18.2) 32 632 25 047 (74.8) 8421 (25.2) 33 468 3691 (75.3) 1209 (24.7) 4900
2011 27 392 (81.8) 6093 (18.2) 33 485 26 340 (76.6) 8061 (23.4) 34 401 3903 (78.3) 1084 (21.7) 4987
2012 27 945 (82.6) 5880 (17.4) 33 825 27 579 (78.2) 7696 (21.8) 35 275 3850 (79.8) 972 (20.2) 4822
2013 26 778 (82.1) 5823 (17.9) 32 601 27 147 (77.4) 7910 (22.6) 35 057 3826 (79.2) 1006 (20.8) 4832
Sex
Women 58 101 (80.2) 14 369 (19.8) 72 470 58 492 (75.9) 18 535 (24.1) 77 027 18900 (77.0) 5645 (23.0) 24 545
Men 76 443 (82.7) 15 977 (17.3) 92 420 71 273 (75.7) 22 908 (24.3) 94 181 — — —
Deprivation quintile
Least deprived 28 370 (79.9) 7148 (20.1) 35 518 17 880 (74.7) 6060 (25.3) 23 940 3981 (75.9) 1264 (24.1) 5245
2 29 640 (81.7) 6618 (18.3) 36 258 22 338 (75.6) 7221 (24.4) 29 559 4217 (78.6) 1151 (21.4) 5368
3 28 595 (82.2) 6187 (17.8) 34 782 25 788 (75.7) 8256 (24.3) 34 044 3974 (77.2) 1174 (22.8) 5148
4 26 826 (82.5) 5709 (17.5) 32 535 30 690 (75.8) 9788 (24.2) 40 478 3782 (76.9) 1137 (23.1) 4919
Most deprived 21 113 (81.8) 4684 (18.2) 25 797 33 069 (76.6) 10 118 (23.4) 43 187 2946 (76.2) 919 (23.8) 3865
Route to diagnosis
Screening 14 001 (91.4) 1315 (8.6) 15 316 — — — — — —
Two-week wait 46 045 (98.5) 722 (1.5) 46 767 45 417 (99.1) 414 (0.9) 45 831 7392 (98.7) 96 (1.3) 7488
Emergency presentation 26 762 (70.3) 11 309 (29.7) 38 071 38 698 (63.8) 21 980 (36.2) 60 678 4879 (65.0) 2630 (35.0) 7509
GP referral 30 583 (77.9) 8667 (22.1) 39 250 25 629 (72.4) 9761 (27.6) 35 390 3859 (72.8) 1439 (27.2) 5298
Inpatient elective 4635 (78.1) 1300 (21.9) 5935 2036 (73.7) 727 (26.3) 2763 195 (69.1) 87 (30.9) 282
Other outpatienta 9174 (76.5) 2825 (23.5) 11 999 14 294 (77.8) 4072 (22.2) 18 366 2013 (77.4) 587 (22.6) 2600
Death certificate onlya 0 (0) 70 (100) 70 2 (1.2) 161 (98.8) 163 0 (0) 15 (100) 15
Unknown 3344 (44.7) 4138 (55.3) 7482 3689 (46.0) 4328 (54.0) 8017 562 (41.5) 791 (58.5) 1353
Died within 30 days
Yes 4307 (39.7) 6543 (60.3) 10 850 13 811 (43.0) 18 326 (57.0) 32 137 635 (26.7) 1741 (73.3) 2376
No 130 237 (84.5) 23 803 (15.5) 154 040 115 954 (83.4) 23 117 (16.6) 139 071 18265 (82.4) 3904 (17.6) 22 169
Abbreviation: CWT¼ Cancer Waiting Times monitoring dataset. All w2 P-values are Po0.001 except deprivation for ovarian cancer: P¼ 0.015, and sex for lung cancer: P¼ 0.211.
aThese categories appear in the Routes to Diagnosis dataset, but are not recorded separately in CWT.
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a similar proportion of cases with stage IV and missing stage
tumours were not recorded (24%).
Patients with more comorbidity were less likely to be recorded
in CWT (Figure 1). For women with ovarian cancer, those with no
comorbidities were 30% more likely to have a CWT record than
those with the most comorbidity.
Patients who died within 30 days of diagnosis were much less
likely to have a CWT record, ranging from 60% (colorectal and
lung cancers) to 73% (ovarian cancer), but 15 18% of those who
survived at least 30 days were also not captured (Table 1), with a
similar J-shaped age pattern to that of the whole cohort.
For all three cancers, 1-year net survival was far lower among
patients who were not captured by CWT than among those who
were (colorectal cancer: 52.2% (95% CI, 51.6 52.8%) compared to
81.4% (81.2 81.7%); lung cancer: 17.0% (16.6 17.4%) compared
to 39.0% (38.7 39.2%); ovarian cancer: 40.4% (39.1 41.7%)
compared to 77.1% (76.4 77.7%); Table 2). The differences
generally increased with increasing age, stage, and deprivation. The
differences were particularly stark for those with stage IV disease.
There was very little difference in survival, among the youngest
patients (aged 15 44 years), between those who did and did not
appear in CWT.
DISCUSSION
Using a new approach to examine the English CWT, we linked
individual data from several sources to describe the characteristics
and short-term survival of patients who were not included in the
dataset. Around one-fifth of patients diagnosed with colorectal,
lung, or ovarian cancer during 2009–2013 did not have a CWT
record. Proportions were highest among elderly patients and those
with comorbid conditions, mirroring patterns for those with
missing stage information (Adams et al, 2004; Worthington et al,
2008). Patients missing from CWT were also more likely to have
advanced disease or missing stage information: these factors are
highly correlated (Barclay et al, 2016). However, more than a
quarter of the youngest patients and more than 10% of those with
early-stage disease also lacked a CWT record, suggesting that the
recording of CWT data could be improved.
Several mechanisms may help explain the pattern and extent of
missing records. Some treatments may not be well recorded (e.g.,
pain relief or transfusions). The CWT does not include data on
patients who died before treatment could commence, even if a
decision to treat had been made. However, in our data, only 22%,
44%, and 31% of colorectal, lung, and ovarian cancer patients
without a CWT record, respectively, died within 30 days of
diagnosis. Services not commissioned by the NHS are also beyond
the scope of CWT data collection, so patients treated in the private
sector, including palliative care in non-NHS organisations, are not
captured (Cancer Waiting Times Team, 2015). The extent of this is
unclear, but it is reported that around 11% of the UK population
has some private health insurance (The King’s Fund, 2014). The
proportion of colorectal and ovarian cancer patients included in
CWT was indeed lower among those in the most affluent quintile,
who are more likely to seek private care.
A CWT record may be missing because of a clinical decision not
to treat a patient: this may explain why older and sicker patients are
less likely to be included. Indeed, under- or sub-optimal treatment in
the elderly has been reported in England (National Cancer Equality
Initiative, 2012; Forrest et al, 2014; Lawler et al, 2014).
One-year survival was generally much lower among patients
with no CWT record, but no survival differences were found
among the youngest patients between those with and without a
record. This suggests that younger patients may well have had
treatment that was not captured in CWT.
There may be some administrative under-reporting by which
patients received treatment that was not recorded in CWT. The
presence in CWT records of patients who received ‘subsequent
treatment’ without any record of first treatment (5–9% depending
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Figure 1. Age, level of comorbidity, and stage at diagnosis of colorectal, lung, and ovarian cancer patients by presence of a matching record in
the Cancer Waiting Times monitoring dataset.
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on the cancer) lends weight to this. The proportion of patients with
no CWT record was also higher among those with missing
information on stage and with an unknown route to diagnosis,
suggesting that there is a group of patients whose information is
generally poorly captured, due to shortcomings in data transmis-
sion system or clinical documentation.
Our novel approach offers a clear picture of the characteristics
of patients who are not included in CWT, but it cannot fully
illuminate the mechanisms of this incompleteness. The extent to
which the missing data create scope for selection bias must be
considered, especially if the reason that patients are not included is
related to whether they meet the waiting times target. The
generalisability of results from CWT to the whole population of
cancer patients recorded in the cancer registration data may be
limited, because they do not reflect the outcomes for patients who
were treated outside the NHS, or of patients who were not captured
despite having received some treatment. These sources of bias
should be considered when interpreting the results or using the
CWT data to evaluate cancer outcomes at patient level.
The CWT dataset is an important source of data: it allows
monitoring of key indicators of NHS performance in cancer care
and the targets encourage timely treatment. However, researchers
and policy-makers should be aware of these limitations in the
completeness and representativeness of the CWT data, and should
draw any conclusions with appropriate caution.
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